吾視保眼藥水

Land: Taiwan

Språk: kinesisk

Kilde: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktiv ingrediens:

Tetryzoline Hydrochloride (eq to Tetrahydrozoline Hydrochloride)

Tilgjengelig fra:

明盟實業有限公司 台北市信義路四段３８０號７樓 (14085628)

ATC-kode:

S01GA52

Legemiddelform:

點眼液劑

Sammensetning:

Tetryzoline Hydrochloride (eq to Tetrahydrozoline Hydrochloride) (5232000330) 0.5MG

Enheter i pakken:

滴瓶裝

Klasse:

製　劑

Resept typen:

須由醫師處方使用

Produsert av:

URSAPHARM ARZNEIMITTEL GMBH INDUSTRIESTRASSE 35 66129 SAARBRUCKEN,GERMANY DE

Terapeutisk område:

tetryzoline, combinations

Indikasjoner:

眼睛受刺激、結膜炎、結膜充血

Produkt oppsummering:

註銷日期: 2020/03/27; 註銷理由: 許可證已逾有效期; 有效日期: 2019/06/23; 英文品名: VASOPOS EYE DROPS

Autorisasjon status:

已註銷

Autorisasjon dato:

1981-06-23

Informasjon til brukeren

Product information, please read carefully!
VASOPOS®
Eye Drops
CONTENTS:
1ml of isotonic buffered solution contains:
Tetryzoline Hydrochloride
0.50
mg
EXCIPIENT:
1ml of isotonic buffered solution contains:
Chlorhexidine Gluconate 0.05
mg
Potassium Dihydrogen Phosphate
1.13
mg
Dipotassium Phosphate 2.50
mg
Sorbiol
39.00
mg
Water for Injections
or Highly Purified Water ad
1.00
ml
INDICATIONS:
Allergic and non-specific conjunctivitis,mechanical and chemical
irritations of the anterior eye.
CONTRAINDICATIONS:
Vasopos® should not be used when the following conditions and
diseases occur:
Allergic reactions to one of the ingredients,rhinitis
sicca,closed-angle glaucoma,children under
the age of 2 years.
Patients with servere heart or circulatory diseases (e.g. coronary,
heart, disease, hypertension,
pheochromocytoma),hormonal disturbances (e.g. hyperthyroidism,diabetes
mellitus) and
patients who are treated with monoamine oxidase inhibitors or other
potential hypertensive
drugs should only be treated with Vasopos after a careful risk-benefit
analysis by a physician.
SIDE-EFFECTS:
Occasionally redness,the sensation of burning or dryness of the
conjunctiva and effects on the
total body (hypertension, nervousness, palpitation of the
heart,headache) have been reported.
Tetryzoline -containing eye drops may temporarily cause blurred
vision, irritation of the
conjunctiva or in rare cases a widening of the pupil.
Special care should be taken with new borns and children under the age
of 3 years concerning
overdosing (e.g. because of swallowing). In case of accidental
swallowing call your doctor
immediately. Overdosing my lead to heart and circulatory disturbances
such as hypertension,
palpitation of the heart, speeding or slowing of the heart-beat.
INTERACTIONS:
Concurrent therapy with monoamine oxidase inhibitors or tricyclic
antidepressants may increase
the vasoconstrictive effect and therefore raise the blood pressure.
DOSAGE AND DIRECTIONS FOR USAGE:
If not otherwise prescribed, instill 1 drop 2 to 3 times daily into
the